Monitor the upcoming corporate strategy webcast on September 10, 2026, for details on ROBBIN trial execution and potential updates on the BATTMAN termination fallout. The stock's reaction will depend on investor sentiment regarding the trade-off between the promising ROBBIN opportunity and the loss of the BATTMAN data readout.
Drugs in focus
AGEN drug pipeline →botensilimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
- Next catalyst
- None dated
What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $7.49entry
- T+1 · 3mo ago −7.08%α −7.69% · $6.96
- T+5 · 3mo ago −6.54%α −7.75% · $7.00
- T+20 · 3mo ago +10.01%α +9.41% · $8.24
- T+60 · 18d ago −8.68%α −7.01% · $6.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from $25.7M), driven by $6.4M in pre-commercial BOT+BAL product revenue and $28.1M in non-cash royalty revenue. The company highlighted its oversubscribed $85M private placement to fund the Phase 3 ROBBIN trial, but also disclosed the termination of the BATTMAN Phase 3 study due to funding prioritization. The filing is neutral as the revenue beat is largely non-cash royalty revenue, and the strategic pivot to ROBBIN comes at the cost of the BATTMAN trial, creating offsetting signals for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Total revenue for Q2 2026 was $34.5M, up from $25.7M in Q2 2025.
- Pre-commercial BOT+BAL product revenue was $6.4M in Q2 2026, up from $4.6M in Q1 2026.
- Non-cash royalty revenue was $28.1M in Q2 2026, up from $24.8M in Q2 2025.
- Agenus completed an oversubscribed $85M private placement in July 2026 to support the ROBBIN trial.
- Agenus discontinued funding for the Phase 3 BATTMAN trial, leading to its termination by CCTG.
- Cash and cash equivalents were $35.0M as of March 31, 2026, with an additional $11.7M in net proceeds from ATM sales received post-quarter-end.
- The company expects the upfront proceeds from the private placement to support operations through Q3 2027.
Financial Impact
Revenue of $34.5M in Q2 2026, with $28.1M being non-cash royalty revenue. The $85M private placement provides a cash runway through Q3 2027.
Risk Factors
- Termination of the BATTMAN Phase 3 trial removes a key pipeline catalyst and may raise questions about clinical strategy.
- Reliance on non-cash royalty revenue for the majority of reported revenue does not provide actual cash flow.
- Execution risk for the large, global Phase 3 ROBBIN trial, which is still in the initiation phase.
- Potential shareholder dilution from the exercise of milestone-aligned warrants, which could provide up to $255M in additional proceeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336780 |
| Document: agen-ex99_1.htm | 0001193125-26-336780 |
| Document: 0001193125-26-336780-index-headers.html | 0001193125-26-336780 |
| Document: 0001193125-26-336780-index.html | 0001193125-26-336780 |
| Document: 0001193125-26-336780.txt | 0001193125-26-336780 |
| 8-K Data (Synthetic) | 0001193125-26-336780 |
Track record
12 reports on AGEN
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Viewing Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers